| 产品详情 |
| Edit |   |
|---|
| Product Name | ATR/CDK Inhibitor, NU6027 |
|---|
| Description | Purity ~95% (HPLC). A cell-permeable, pyrimidine derivative that acts as an ATP-competitive CDK Inhibitor (Ki=2.5uM for CDK1, and Ki=1.3uM for CDK2), and demonstrates cytostatic properties among a panel of 57 cancer cell lines. Also inhibits ATR kinase (IC50=6.7uM in MCF7 cells), but does not interfere with irradiation-induced autophosphorylation of DNA-PK or ATM. Potentiates a range of DNA-damaging cytotoxic drugs such as hydroxyurea (1.8-fold) and cisplatin (1.4-fold) at 10 µM, but not the anti-mitotic paclitaxel. Attenuates G2/M arrest following DNA damage and inhibits RAD51 focus formation. Shown to be synthetically lethal when DNA single-strand break repair is impaired in PARP-inhibited cells. Formula: C11H17N5O2 Molecular Weight: 251.28 Solubility: DMSO (10mg/ml, clear, blue solution) |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | ATR/CDK Inhibitor, NU6027 (2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, ATR Inhibitor, NU6027, CDK2 Inhibitor) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217203 |
|---|
| Price | |
|---|
| Order / More Info | ATR/CDK Inhibitor, NU6027 from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|